Mold Toxicity Test: What Homeowners Need to Know

We may earn commission from links on this page. Lead-form submissions are forwarded to local inspector partners. How we research and review.

A mold toxicity test is rarely a single thing. The phrase is used loosely to describe at least four different laboratory tests, each measuring something different and each with a different evidence base. This guide explains what those tests do, what mainstream medical organizations say about their clinical role, and how the home-inspection side of the problem fits in. The site’s expertise is residential inspection, not medical diagnostics — the framing here is what homeowners should know before talking to a doctor, never a substitute for that conversation. Our editorial approach to health-adjacent topics is documented on our methodology page; the summaries below reflect CDC, NIEHS, and ATSDR guidance current as of 2026.

What is a mold toxicity test?

“Mold toxicity test” is consumer-market shorthand for several distinct medical tests, marketed under a unified umbrella that doesn’t quite match how clinical medicine categorizes mold-related illness. The four main categories are urine mycotoxin tests, IgE allergy panels (blood or skin prick), IgG antibody panels, and various biomarker or auxiliary tests (visual contrast sensitivity, MARCoNS swabs, inflammation panels).

Each of these measures something different. A mycotoxin test looks for mold-toxin metabolites in urine. An IgE panel looks for allergic sensitization. An IgG panel looks for past exposure. The auxiliary tests measure inflammation markers or neurological function indirectly. Bundling them under “mold toxicity test” obscures that they answer different questions with different levels of clinical validation.

Urine mycotoxin testing

Urine mycotoxin tests are the most prominently marketed option. They look for chemicals like ochratoxin A, aflatoxin, trichothecenes, gliotoxin, and zearalenone in a urine sample. Several private labs offer these tests directly to consumers, often at $300 to $700 per panel.

The interpretation challenges are well documented. Mycotoxins enter the human body through food (grains, coffee, dried fruit, peanuts, certain spices) as well as inhalation, so a positive urine result doesn’t isolate home mold as the cause. Peer-reviewed clinical validation literature is limited. Public-health agencies including NIEHS and CDC have not endorsed urine mycotoxin testing as a validated diagnostic tool for mold-related illness. A physician may still order one as part of a broader workup; the result should be interpreted in clinical context.

IgE testing for mold allergy

IgE testing is the most well-established mold-related test in mainstream medicine. It is designed to detect allergic sensitization — an immune system that reacts allergically to specific mold species on exposure. Testing is typically done by blood draw measuring specific IgE antibodies or by skin-prick test in an allergist’s office.

A positive IgE result tells you the immune system has been sensitized to that mold and reacts to it. It does not, on its own, tell you the home currently has elevated mold levels, or that broader systemic symptoms are mold-related. IgE testing is most useful for patients with allergy-pattern symptoms (sneezing, watery eyes, asthma flares, eczema) and is ordered under a board-certified allergist’s care.

IgG antibody panels

IgG antibody panels measure long-term antibody responses to mold antigens. They are sometimes promoted as a way to detect chronic exposure. The clinical interpretation is murky: IgG antibodies generally indicate past exposure to an antigen, but most adults will show some IgG reactivity to common environmental molds simply from living and breathing in the world.

Public-health bodies including NIEHS and CDC have not endorsed IgG panels as a validated diagnostic test for mold-related illness. They retain a narrow role in specific conditions like hypersensitivity pneumonitis, when ordered and interpreted by a specialist. For broader “mold toxicity” concerns, IgG panels do not currently provide diagnostic certainty — and consumers should not treat a positive result as a self-diagnosis.

Auxiliary and investigational tests

Several other tests appear in the mold-toxicity testing landscape. Visual contrast sensitivity (VCS) tests assess the patient’s ability to distinguish shades of gray; some practitioners use them as a screening tool. MARCoNS nasal swabs look for specific antibiotic-resistant bacteria sometimes associated with chronic inflammatory response syndromes.

Various inflammation biomarker panels — measuring complement proteins, MMP-9, leptin, TGF-beta, and others — are also marketed in this space. None of these is universally accepted as a stand-alone diagnostic for mold toxicity. A physician evaluating a patient’s specific clinical picture may incorporate some of them into a broader workup. A consumer ordering them without medical interpretation is unlikely to extract actionable information.

Where mainstream medical organizations stand

The CDC’s mold guidance acknowledges that exposure to indoor mold can cause allergic reactions, asthma symptoms, and irritant effects, and that immunocompromised individuals face infection risk. It does not endorse a specific consumer “mold toxicity test.” The EPA’s stance is similar, focused on environmental remediation rather than medical testing.

NIEHS and CDC guidance does not endorse urine mycotoxin testing or IgG mold panels as validated diagnostic tools for mold-related illness. ATSDR’s clinical guidance emphasizes individualized assessment by a physician familiar with the patient’s history. None of these positions deny that people get sick from mold exposure — they decline to endorse specific consumer-marketed tests as reliable diagnostic shortcuts.

What homeowners can address on the home side

The environmental side of the problem is where homeowners have direct leverage. A professional mold inspection can document visible growth, identify moisture sources, take laboratory air or surface samples when warranted, and produce a written report. The inspection answers a building question — is there a mold problem here, and where is the moisture coming from — not a medical one.

This separation matters. A negative human test does not prove the home is mold-free. A positive home test does not prove the occupants’ symptoms are mold-related. Each side of the problem requires its own kind of expertise. The credible path forward typically combines both: the physician handles the body, the inspector handles the building.

Preparing for a doctor’s appointment

If you suspect mold exposure is contributing to symptoms, the most useful preparation for a medical appointment is not a self-ordered mycotoxin test. It is a clear timeline and environmental documentation. When did symptoms start? Who in the household is affected? What changed in the home around that time — a flood, a leak, basement seepage, new HVAC work, recent renovations? Do symptoms improve when the affected person spends extended time away from the home?

Photographs of any visible growth, moisture meter readings if available, and any existing inspection report give the physician environmental context that medical lab tests alone won’t. A board-certified allergist or pulmonologist will know which targeted tests are appropriate. Our overview of human mold toxicity testing covers the medical-side decision tree in more depth.

Why this market grew so fast

Direct-to-consumer mold testing expanded rapidly during the 2010s and 2020s. Several forces drove the growth: legitimate frustration among patients with chronic unexplained symptoms, the rise of functional and integrative medicine practices that often order these panels, social media communities sharing experiences, and aggressive direct-to-consumer marketing by labs.

The underlying environmental concern — chronic indoor moisture and mold exposure is a real health issue — is well founded. The diagnostic certainty implied by consumer-marketed panels often exceeds what the underlying clinical evidence supports. Homeowners can navigate this landscape by working with licensed physicians for the medical side and qualified inspectors for the home side, treating any single consumer-ordered panel as one data point rather than a verdict.

When mold-related medical concern justifies urgency

Several scenarios warrant prompt medical evaluation regardless of how the testing question gets resolved. Immunocompromised household members — transplant recipients, patients on chemotherapy, those with HIV/AIDS or severe asthma — who develop respiratory symptoms in a home with visible mold need timely evaluation; aspergillus and other fungal infections are known risks. Persistent respiratory symptoms in any household member, especially if accompanied by wheezing or shortness of breath, justify a primary care visit and possible pulmonology referral.

Symptoms that consistently improve when an affected person leaves the home for several days and recur on return are a clinical pattern worth flagging to a physician — that pattern is consistent with environmental triggering, regardless of the underlying mechanism.

The home-side action plan

Whatever the medical workup shows, the home side is straightforward: locate the moisture, fix it, remediate affected materials, verify the work. A qualified inspector can scope the problem and produce a written report. Front Range homes have recurring patterns — basement seepage, ice-dam leaks, condensation on poorly insulated walls — that experienced local inspectors recognize quickly.

How to use test results without overinterpreting them

Test results are most useful when treated as one data point in a larger picture. A positive IgE result for Alternaria, combined with seasonal allergy symptoms and a home with documented basement humidity issues, supports a coherent clinical and environmental story. The same isolated IgE result with no symptoms and no home moisture findings is less actionable.

Similarly, a positive urine mycotoxin result in a patient who has been eating significant quantities of grains and coffee may simply reflect dietary exposure. The same result in a patient with documented water damage at home, symptoms consistent with environmental triggering, and corroborating environmental sampling has more weight in the clinical picture. The interpretation requires the surrounding context that a stand-alone lab report cannot supply.

Cost and insurance considerations

Direct-to-consumer mycotoxin and IgG panels typically cost $300 to $700 each and are rarely covered by health insurance. Physician-ordered IgE testing for a documented clinical reason is commonly covered. Imaging and microbiology for suspected fungal infection are typically covered when ordered for defined diagnostic purposes.

On the home side, homeowners insurance rarely covers the inspection itself but may cover remediation when growth stems from a covered peril. Insurance coverage for chronic moisture problems is often more limited than for sudden water events. Confirming coverage with your specific insurer before commissioning either kind of testing avoids surprises.

References

• CDC mold and health overview — Centers for Disease Control and Prevention
• NIEHS overview of mold and human health — National Institute of Environmental Health Sciences
• ATSDR clinical guidance on mold — Agency for Toxic Substances and Disease Registry
• EPA mold and health guidance — U.S. Environmental Protection Agency

If you’re addressing the environmental side of a suspected mold problem in the Front Range, reach out through our contact page for a referral to a vetted independent inspector.